Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 10/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028189 | 0.86 | AHCY (0.46) | AHCYRAB9AKDM4EMEN1KMT2A | |
| SCHEMBL1027422 | 0.84 | AHCY (0.54) | AHCYALDH1A1 | |
| SCHEMBL1028138 | 0.84 | AHCY (0.51) | AHCYALDH1A1 | |
| SCHEMBL1027747 | 0.84 | ALDH1A1 (0.41) | AHCYKEAP1NFE2L2TSHRRAB9A | |
| SCHEMBL1027427 | 0.82 | AHCY (0.43) | AHCYTSHRKDM4EMEN1KMT2A | |
| SCHEMBL11974756 | 0.82 | AHCY (0.52) | AHCY | |
| SCHEMBL1026047 | 0.81 | AHCY (0.51) | AHCYKEAP1NFE2L2ALDH1A1TDP1 | |
| SCHEMBL1026705 | 0.80 | KEAP1 (0.49) | KEAP1NFE2L2NPC1TSHRRAB9A | |
| SCHEMBL1026661 | 0.80 | AHCY (0.42) | AHCYKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1025604 | 0.80 | AHCY (0.42) | AHCYKEAP1NFE2L2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | AHCY 4108/4885KEAP1 776/4885NFE2L2 1949/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | AHCY 4/4885KEAP1 754/4885NFE2L2 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.